GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to redu...
Nanochon, a medical device company developing Chondrograft, a novel patented implant for the treatment of articular cartilage defects of the knee, announ...
Aurisco Pharmaceutical, a leading global Oligonucleotide and Peptide (TIDES) manufacturer, announced that its site in Yangzhou, China has passed the USFDA ...
Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, announced a multi-program collaboration with a San Diego-based...
Drug development is inherently uncertain, with scientific discoveries, manufacturing challenges, regulatory expectations and commercial priorities ...
Pharmaceutical marketing is undergoing a significant transformation as companies balance regulatory complexity, digital disruption, evolving workforce ex...
In biopharma, critical decisions are often shaped by more than clinical data, regulatory insights, or operational metrics. The most important signals m...
Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09 Pharma launches sales increased by 48.3%, reaching €1.3 bil...
-Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin Am...
SCIEX, a Danaher company and leader in life science analytical technologies, announced new solutions designed to help clinical laboratories move from sam...
Lundbeck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 rece...
The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its own co...
Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating B...
Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Bio...
© 2026 Biopharma Boardroom. All Rights Reserved.
